A phase I dose-escalation trial to assess safety and efficacy of allogeneic MSC based-treatment (cellistem-OA) in patients with symptomatic knee osteoarthritis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
24
Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
Clínica Universidad de los Andes
Santiago, XIII, Chile
RECRUITINGIncidence of adverse events
Time frame: 6 months
Change in WOMAC score
Time frame: 6 months
Change in VAS score
Time frame: 6 months
Changes in structural joint assessment by MRI
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.